ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Maxygen, a biotechnology firm specializing in directed evolution techniques, plans to close its European subsidiary in Hørsholm, Denmark, and consolidate in Redwood City, Calif., where it will add 25 employees. The move is expected to yield $10 million in annual cost savings. The company's lead drug candidate, MAXY-G34 for the treatment of the blood disorder neutropenia, is currently in Phase II clinical trials. Separately, Maxygen has received a payment of $7 million from a biofuels collaboration between Shell Oil and Codexis. Maxygen spun off Codexis in 2003 with a license to use its MolecularBreeding technology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter